Adjust for infinite possibilities.
With the revolutionary Light Adjustable Lens™
Now with ActivShield™ Technology
ActivShield is a revolutionary UV protection layer built into the newly updated Light Adjustable Lens
How the Light Adjustable Lens Works
The Light Adjustable Lens (LAL) is the first and only lens that is fully adjustable after cataract surgery.
Unlike traditional cataract surgery and lens implant options, the LAL gives surgeons the opportunity for multiple lens adjustments after surgery. UV light treatments after surgery correct refractive error and dial in optimized vision.
1 Perform a standard cataract implant procedure using the RxSight Light Adjustable Lens.
The LAL is implanted using standard cataract surgery techniques. However, because the lens will be adjusted using UV light after surgery and healing has occurred, surgeons can simplify their pre-surgical diagnostic workflow and reduce the anxiety and burden on patients.
2 Determine refractive error with a standard refraction technique, optimizing refraction with patient input after healing is complete.
Standard refraction techniques can be used after surgery to measure refractive error for LAL patients. This process can be more precise than ever, accounting for lens shift and refractive changes during the healing process, through the LAL’s ability to be adjusted weeks after surgery. Unlike standard lens implants, patients have direct input into their refractive correction as they experience and test vision options during the light adjustment phase.
3 Refractive error is corrected with the RxSight Light Delivery Device (LDD).
The LDD delivers targeted UV light to shape the LAL and offer precise adjustment and vision for each patient. Surgeons can adjust the lens over a series of treatments to ensure each patient achieves vision that matches their goals and expectations.
Adjust for Improved Clinic Flow
The LAL's flexibility can help simplify both the pre- and post-operative workflow of your practice in the following ways:
Simplifies pre-surgical diagnostic workflow by extending the ability to adjust the lens refraction after surgery
Reduces patient anxiety by offering them control and choice in their final vision outcome
The LDD's small clinic footprint is simple to incorporate into your post-surgical workflow
Once you see the results in your own patients, from complex cataracts to ‘straightforward cases,’ it’s hard to imagine looking a patient in the eye and offering anything else.
When I say to patients ‘the Light Adjustable Lens is the most precise implant on Mother Earth and, for the first time in history, we can truly customize your implant...in your eye,’ they get it and want it.
RxSight’s Light Adjustable Lens is the biggest improvement in cataract surgery in my career. We can now deliver the highest level of vision to our patients, tailored to their needs.
I love RxSight and the Light Adjustable Lens, and I’m thrilled to be using the technology. With the LAL, my toughest to please patients have become my happiest. I’m so thankful you brought this to market.
The ability to change the shape of a lens to perfectly match the eye after healing has resulted in the most precise results I have ever seen!
80% of our first 200 LAL patients saw 20/20 or better at both distance and near without glasses. As the LAL also provides the least amount of glare and halos, this makes the LAL the most accurate AND best quality IOL in the world today.
Adjust for Better Patient Outcomes
Many patients can benefit from the exciting opportunities created by the LAL. Patients who may be candidates include those who are:
Looking to optimize their vision and outcomes
Able to make and keep the additional 3 to 5 appointments needed for optimal vision with the RxSight LAL
Found to have pre-existing corneal astigmatism of ≥ 0.75 diopters
Able to comply with wearing UV protective glasses until final light treatment
Learn More About the Light Adjustable Lens
IMPORTANT SAFETY INFORMATION
INDICATIONS: The Light Adjustable Lens and Light Delivery Device system is indicated for the reduction of residual astigmatism to improve uncorrected visual acuity after removal of the cataractous natural lens by phacoemulsification and implantation of the intraocular lens in the capsular bag in adult patients:
- With preexisting corneal astigmatism of ≥ 0.75 diopters
- Without preexisting macular disease
The system also reduces the likelihood of clinically significant residual spherical refractive errors.
CONTRAINDICATIONS: The Light Adjustable Lens is contraindicated in patients who are taking systemic medication that may increase sensitivity to ultraviolet (UV) light as the LDD treatment may lead to irreversible phototoxic damage to the eye; patients who are taking a systemic medication that is considered toxic to the retina (e.g., tamoxifen) as they may be at increased risk of retinal damage during LDD treatment; patients with a history of ocular herpes simplex virus due to the potential for reactivation from exposure to UV light; patients with nystagmus as they may not be able to maintain steady fixation during LDD treatment; and patients who are unwilling to comply with the postoperative regimen for adjustment and lock-in treatments and wearing of UV protective eyewear.
WARNINGS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting an IOL in a patient with any of the conditions described in the Light Adjustable Lens and LDD Professional Use Information brochure. Caution should be used in patients with eyes unable to dilate to a pupil diameter of ≥ 7 mm to ensure that the edge of the Light Adjustable Lens can be visualized during LDD light treatments; patients who the doctor believes will be unable to maintain steady fixation that is necessary for centration of the LDD light treatment; and patients with sufficiently dense cataracts that preclude examination of the macula as patients with preexisting macular disease may be at increased risk for macular disease progression.
PRECAUTIONS: The long-term effect on vision due to exposure to UV light that causes erythropsia (after LDD treatment) has not been determined. The implanted Light Adjustable Lens MUST undergo a minimum of 2 LDD treatments (1 adjustment procedure plus 1 lock-in treatment) beginning at least 17-21 days post-implantation. All clinical study outcomes were obtained using LDD power adjustments targeted to emmetropia post LDD treatments. The safety and performance of targeting to myopic or hyperopic outcomes have not been evaluated. The safety and effectiveness of the Light Adjustable Lens and LDD have not been substantiated in patients with preexisting ocular conditions and intraoperative complications.
Patients must be instructed to wear the RxSight-specified UV protective eyewear during all waking hours after Light Adjustable Lens implantation until 24 hours post final lock-in treatment. Unprotected exposure to UV light during this period can result in unpredictable changes to the Light Adjustable Lens, causing aberrated optics and blurred vision, which might necessitate explantation of the Light Adjustable Lens.
ADVERSE EVENTS: The most common adverse events (AEs) reported in the randomized pivotal trial included cystoid macular edema (3 eyes, 0.7%), hypopyon (1 eye, 0.2%), and endophthalmitis (1 eye, 0.2%). The rates of AEs did not exceed the rates in the ISO historical control except for the category of secondary surgical interventions (SSI); 1.7% of eyes (7/410) in the Light Adjustable Lens group had an SSI (p < .05). AEs related to the UV light from the LDD include phototoxic retinal damage causing temporary loss of best spectacle corrected visual acuity (1 eye, 0.2%), persistent induced tritan color vision anomaly (2 eyes, 0.5%), persistent induced erythropsia (1 eye, 0.3%), reactivation of ocular herpes simplex Infection (1 eye, 0.3%), and persistent unanticipated significant increase in manifest refraction error (≥ 1.0 D cylinder or MRSE) (5 eyes, 1.3%).
CAUTION: Federal law restricts this device to sale by or on the order of a physician.
Click here for Instructions for Use
For clinical study data, please see the FDA Summary of Safety and Effectiveness.
